Crispr-Cas9 As A Tool For Correctng Oncogenic Mutations In Vitro Cancer Models

Abstract

CRISPR-Cas9 gene editing has proven to become a groundbreaking method of the accurate control of genetic disease-causing lesions. The current research examines the practicality, effectiveness, and practical implications of remediating the oncogenic mutations in the in vitro models of human cancer through the CRISPR-Cas9. Guide RNAs and homology-directed repair templates were constructed to target representative driver mutations, and edited clones were obtained and verified by sequencing, protein expression analysis and functional assays. These findings show that the mutation of interest has been repaired in a statistically significant proportion of edited cells, and that end joining via homology-directed repair is possible in addition to the overwhelmingly dominant non-homologous end joining. Edit-fixed clones showed significant decreases in proliferation, reactivation of apoptotic pathways and oncogenic signaling were normalized in comparison with unedited mutant controls. Genome-wide off-target screening reflected few unwanted edits at the optimum design and delivery condition.

Comparative analysis identifies the conceptual superiority of the CRISPR-based correction to traditional chemotherapy, targeted drug therapy, and strategies of the viral gene addition as the lesion in the genome is fixed instead of suppressed. Even though it promises to be a durable and accurately repairing genetic cure, there are still critical issues, such as the lack of HDR efficacy, delivery issues, and unresolved long-term safety and ethical aspects. Altogether, this study represents proof-of-concept evidence that oncogenic mutation correction in regulated in vitro models using CRISPR-Cas9 can reverse malignant phenotypes, which provides a basis of future in vivo validation, translational development, and combination with developing cancer immunotherapies and precision oncology models. These results justify further optimization of in vivo editing of chemistry, in vivo delivery vehicles and in vivo safety analysis to permit responsible advancement to initial in-human applications of mutation-correcting genome therapies in solid tumours and in haematological malignancies both.